Dose tapering of dupilumab in patients with persistently controlled atopic dermatitis: a Spanish multicenter cohort study

Abstract

Dose tapering of dupilumab in patients with persistently controlled atopic dermatitis: a Spanish multicenter cohort study Dear Editor, Atopic Dermatitis (AD) is a skin disorder characterized by eczematous lesions and relapsing pruritus, caused by disrupted skin barrier function and skin inflammation. 1,2 Dupilumab, a monoclonal antibody against IL-4 receptor a, is approved for adults with AD at a loading dose of 600 and 300 mg every 2 weeks (Q2W). [1][2][3][4][5] Currently, there is no consensus about dupilumab dose reduction in well-controlled disease, though real studies suggest it might maintain efficacy. 1,[3][4][5] The objective of this retrospective cohort study was to describe the characteristics of AD patients on dupilumab doses spaced for controlled disease. BMI, body mass index; IQR, interquartile range. a Chi-squared test. b Mann-Whitney U test. c Student's t-test.